Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Fickert

Showing results (1-10 of 163) with videos related to

Pageof 17
Sort By:
Journal of Hepatology|October 2, 2013
Time to say goodbye to the drug or the model? - why do drugs fail to live up to their promise in bile duct ligated mice?Peter Fickert
Journal of Hepatology|November 28, 2023
Detour of bile acid routes as therapeutic roadmap for cholemic nephropathyPeter Fickert
Gut|June 28, 2022
Bacteria as key players in primary sclerosing cholangitis?Peter Fickert
Journal of Hepatology|October 6, 2016
Bad memories from the gut may cause nightmares for the bile ductsPeter Fickert
Hepatology (Baltimore, Md.)|October 11, 2018
Is This the Last Requiem for Simtuzumab?Peter Fickert
Molecular Aspects of Medicine|November 30, 2013
Molecular pathogenesis of chronic cholestatic liver disease: impact on novel therapeutic approachesPeter Fickert, Bruno Stieger
Annual Review of Pharmacology and Toxicology|September 12, 2019
Drug Therapies for Chronic Cholestatic Liver DiseasesMartin Wagner, Peter Fickert
Biochimica Et Biophysica Acta. Molecular Basis of Disease|March 4, 2019
Preface - Animal models in liver diseasePeter Fickert, Martin Wagner
Journal of Hepatology|July 18, 2017
Biliary bile acids in hepatobiliary injury - What is the link?Peter Fickert, Martin Wagner
Liver International : Official Journal of the International Association for the Study of the Liver|June 5, 2018
Time for the dawn of multimodal therapies and the dusk for mono-therapeutic trials for cholestatic liver diseases?Martin Wagner, Peter Fickert
Pageof 17

Showing results (1-10 of 163) with videos related to

Sort By:
Pageof 17
Journal of Hepatology|October 2, 2013
Time to say goodbye to the drug or the model? - why do drugs fail to live up to their promise in bile duct ligated mice?Peter Fickert
Journal of Hepatology|November 28, 2023
Detour of bile acid routes as therapeutic roadmap for cholemic nephropathyPeter Fickert
Gut|June 28, 2022
Bacteria as key players in primary sclerosing cholangitis?Peter Fickert
Journal of Hepatology|October 6, 2016
Bad memories from the gut may cause nightmares for the bile ductsPeter Fickert
Hepatology (Baltimore, Md.)|October 11, 2018
Is This the Last Requiem for Simtuzumab?Peter Fickert
Molecular Aspects of Medicine|November 30, 2013
Molecular pathogenesis of chronic cholestatic liver disease: impact on novel therapeutic approachesPeter Fickert, Bruno Stieger
Annual Review of Pharmacology and Toxicology|September 12, 2019
Drug Therapies for Chronic Cholestatic Liver DiseasesMartin Wagner, Peter Fickert
Biochimica Et Biophysica Acta. Molecular Basis of Disease|March 4, 2019
Preface - Animal models in liver diseasePeter Fickert, Martin Wagner
Journal of Hepatology|July 18, 2017
Biliary bile acids in hepatobiliary injury - What is the link?Peter Fickert, Martin Wagner
Liver International : Official Journal of the International Association for the Study of the Liver|June 5, 2018
Time for the dawn of multimodal therapies and the dusk for mono-therapeutic trials for cholestatic liver diseases?Martin Wagner, Peter Fickert
Pageof 17